StockNews.com upgraded shares of DBV Technologies (NASDAQ:DBVT - Free Report) from a sell rating to a hold rating in a research note issued to investors on Friday.
A number of other research analysts have also recently commented on the company. HC Wainwright increased their price target on DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research note on Monday, May 5th. JMP Securities increased their price target on DBV Technologies from $10.00 to $15.00 and gave the stock a "market outperform" rating in a report on Thursday, May 1st.
View Our Latest Research Report on DBVT
DBV Technologies Stock Performance
Shares of DBVT stock traded up $0.85 on Friday, hitting $10.98. The company's stock had a trading volume of 106,346 shares, compared to its average volume of 185,938. The company has a market capitalization of $300.74 million, a PE ratio of -2.44 and a beta of -0.66. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $11.19. The stock's 50 day moving average is $7.02 and its 200-day moving average is $4.92.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. The firm had revenue of $0.51 million for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. On average, research analysts forecast that DBV Technologies will post -7.05 earnings per share for the current year.
Hedge Funds Weigh In On DBV Technologies
A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is currently owned by institutional investors and hedge funds.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Articles
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
